Cargando…

Prevalence And Clinical Significance Of Oncogenic CD79B And MYD88 Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China

PURPOSE: In this study, we investigated the prevalence of CD79B and MYD88 mutations and their relation to clinical characteristics in a cohort of Chinese patients with primary testicular diffuse large B cell lymphoma (PT-DLBCL). PATIENTS AND METHODS: We examined the mutational status of CD79B and MY...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yan-ping, Ke, Long-feng, Lu, Jian-ping, Wang, Jian-chao, Zhu, Wei-feng, Chen, Fang-fang, Lin, Shao-feng, Xu, Chun-wei, Wu, Mei-juan, Chen, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884971/ https://www.ncbi.nlm.nih.gov/pubmed/32063711 http://dx.doi.org/10.2147/OTT.S222189

Ejemplares similares

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014)

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
por: Visco, Carlo, et al.
Publicado: (2020)

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
por: Kraan, W, et al.
Publicado: (2013)

CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma
por: Trøen, Gunhild, et al.
Publicado: (2013)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants‐enriched diffuse large B‐cell lymphomas
por: L'Imperio, Vincenzo, et al.
Publicado: (2022)

MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy
por: Chen, Rongrong, et al.
Publicado: (2022)

Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report
por: Huang, Wen-Ye, et al.
Publicado: (2022)

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
por: Munshi, Manit, et al.
Publicado: (2020)

Adaptor protein MyD88 confers the susceptibility to stress via amplifying immune danger signals
por: Yao, Xia-Ping, et al.
Publicado: (2023)

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
por: Ebid, Osama Abd El Hameed, et al.
Publicado: (2023)

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
por: Lee, Ju-Han, et al.
Publicado: (2017)

Identification and Function of Myeloid Differentiation Factor 88 (MyD88) in Litopenaeus vannamei
por: Zhang, Shuang, et al.
Publicado: (2012)

High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment
por: Yu, Sisi, et al.
Publicado: (2018)

Disrupting myddosome assembly in diffuse large B-cell lymphoma cells using the MYD88 dimerization inhibitor ST2825
por: Wang, Xin, et al.
Publicado: (2019)

Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma
por: Fogliatto, Laura, et al.
Publicado: (2019)

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis
por: Vermaat, Joost S., et al.
Publicado: (2020)

Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation
por: Luo, Wu, et al.
Publicado: (2022)

Prognostic relevance of protein expression, clinical factors, and MYD88 mutation in primary bone lymphoma
por: Xu, Yong, et al.
Publicado: (2017)

PB2403: THE FREQUENCY OF L265P MUTATION IN MYD88 GENE AT DIFFUSE LARGE B-CELL LYMPHOMA
por: Dubrovina, Anastasiya, et al.
Publicado: (2023)

Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells
por: Zhu, Yi, et al.
Publicado: (2012)

Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR
por: Niu, Jing, et al.
Publicado: (2020)

PB2355: CORRELATION OF MYD88 AND TNFAIP3 MUTATIONS WITH CLINICO-HEMATOLOGICAL PROFILE IN DIFFUSE LARGE B CELL LYMPHOMA
por: Shaat, Rana, et al.
Publicado: (2023)

Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM
por: Wang, James Q., et al.
Publicado: (2017)

Fisetin-treatment alleviates airway inflammation through inhbition of MyD88/NF-κB signaling pathway
por: Huang, Wei, et al.
Publicado: (2018)

Prognostic Significance of LDH Ratio in Serum/Cerebral Spinal Fluid of Patients with Primary Testicular Diffuse Large B-Cell Lymphoma
por: Liu, Yi-Zhen, et al.
Publicado: (2019)

MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway
por: Guo, Xiuchen, et al.
Publicado: (2023)

MyD88 Polymorphisms and Association with Susceptibility to Salmonella Pullorum
por: Liu, Xian-Qing, et al.
Publicado: (2015)

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
por: Minderman, Marthe, et al.
Publicado: (2023)

Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF-κB) signaling pathway
por: Zhou, Mingyao, et al.
Publicado: (2022)

The Effect of TLR9, MyD88, and NF-κB p65 in Systemic Lupus Erythematosus
por: Wang, Huanan, et al.
Publicado: (2022)

Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients
por: Zhou, Shujuan, et al.
Publicado: (2017)

Expression of TLR4-MyD88 and NF-κB in the Iris during Endotoxin-Induced Uveitis
por: Li, Shang, et al.
Publicado: (2010)

Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling
por: Cardona Gloria, Yamel, et al.
Publicado: (2021)

Clinical significance of disease‐specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma
por: Hattori, Keiichiro, et al.
Publicado: (2017)

PB2397: TRANSCRIPTOME ANALYSIS OF DIFFUSE LARGE B-CELL LYMPHOMA CELLS EXPRESSING MYD88 L265P REVEALS CD44, LGALS3, NFKBIZ AND BATF AS DOWNSTREAM TARGETS OF ONCOGENIC NF-ΚB SIGNALING.
por: Turi, Marcello, et al.
Publicado: (2023)

Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas
por: Shin, Sang-Yong, et al.
Publicado: (2016)

The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma
por: Elbaz, Osama, et al.
Publicado: (2023)

Primary testicular diffuse large B-cell lymphoma: Case series
por: Wang, Qi, et al.
Publicado: (2020)

Lipopolysaccharide-induced NF-κB nuclear translocation is primarily dependent on MyD88, but TNFα expression requires TRIF and MyD88
por: Sakai, Jiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q6vimag8j67rn68dfatanu5k79